What it is
Many autism cases trace to a single disabled copy of a high-confidence risk gene, which leaves too little of its protein. The authors mapped the regulatory enhancers of two such genes, CHD8 and SCN2A, then used CRISPR-based gene activation aimed at those enhancers (eCRISPR-A, with a dCas9-p300 activator) to boost the remaining healthy copy in human stem-cell-derived neurons and cerebral forebrain organoids. About 15% of autism's genetic susceptibility comes from these de novo haploinsufficient mutations, and CHD8 and SCN2A carry an odds ratio above 100 for autism.
Why it matters
There are few treatments for autism beyond managing symptoms, and this points toward correcting the underlying genetic shortfall rather than its effects. Because the method activates a gene's own enhancers, it raises expression through the cell's own regulation, aiming to avoid the overexpression that boosting a haploinsufficient gene too far can cause.
Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.
Filed underCRISPR and Genetic Engineering, Autism Spectrum Disorder Research, Genetics and Neurodevelopmental Disorders